Solexa Q3 Revenues Fall 33 Percent as Company Shifts from MPSS to Sequencing

Nov 13, 2006

NEW YORK (GenomeWeb News) - Solexa today said third-quarter revenues decreased 33 percent as R&D spending rose 21 percent and its net loss decreased 8 percent.

Total receipts for the three months ended Sept. 30 fell to $569,000 from $844,000 in the third quarter of 2005. Solexa said all of its revenues are from its legacy MPSS technology, which the company has now discontinued, and do not include any contribution from its Genome Analysis System DNA sequencing technology.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Under the Watchful Smart Device Eye

Newsweek discusses the privacy issues raised by digital medicine.

The Poor P Value

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

This Week in Nature

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Push for Predictive Genetic Tests

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

Featured White Papers

The Ultimate Guide to Mouse Clinical Trials

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu